novocure(US:NVCR)2026-01-12 12:00Financial Performance - Preliminary full year 2025 net revenues were $655.4 million, an increase of 8% compared to the prior year[4] - Fourth quarter net revenues were $174.4 million, also an increase of 8% compared to the same period in 2024[4] - The U.S. contributed $101.6 million to fourth quarter revenues, followed by Germany at $21.6 million, France at $20.5 million, and Japan at $10.2 million[4] - Cash, cash equivalents, and short-term investments were $448.3 million as of December 31, 2025, after repaying $561 million of convertible notes[4] Product Usage and Development - As of December 31, 2025, there were 4,620 total active patients on TTFields therapy globally, with 4,464 on Optune Gio and 122 on Optune Lua for NSCLC[8] - Optune Gio prescriptions for glioblastoma increased by 6% year-over-year, totaling 1,609 in the fourth quarter[4] - Novocure plans to stop reporting new prescriptions for indications that have been commercially available for over a year starting Q1 2026[7] - The company submitted the final module of its PMA application to the FDA for TTFields therapy for brain metastases from NSCLC in December 2025[7] - Topline data from the Phase 2 PANOVA-4 clinical trial in metastatic pancreatic cancer is expected in Q1 2026[7] - Novocure appointed Frank Leonard as CEO in December 2025, enhancing leadership for upcoming product launches[7] Treatment Risks and Side Effects - Optune Lua may cause treatment-related skin irritation and allergic reactions[24] - Potential adverse effects include overheating of the array leading to pain and local skin burns[24] - Users may experience infections at the site of contact with the arrays[24] - Local warmth and tingling sensations beneath the arrays are reported side effects[24] - Muscle twitching and skin breakdown/ulcers are also potential risks associated with Optune Lua[24]